Targeting Cell Cycle Facilitates E1A-Independent Adenoviral Replication.

Adenoviridae / genetics Adenovirus E1A Proteins / genetics Binding Sites Cell Cycle / drug effects Cell Line, Tumor Cells / drug effects DNA Replication / drug effects DNA, Viral / metabolism Gene Expression Regulation, Viral / drug effects Mutation Promoter Regions, Genetic / genetics Protein Kinase Inhibitors / pharmacology Virus Replication / physiology Humans
CDK4/6 E1A E2F Rb YB-1 adenovirus cell cycle nutlin-3a ribociclib

Journal

Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724

Informations de publication

Date de publication:
29 06 2023
Historique:
medline: 3 7 2023
pubmed: 23 5 2023
entrez: 23 5 2023
Statut: ppublish

Résumé

DNA replication of E1-deleted first-generation adenoviruses (AdV) in cultured cancer cells has been reported repeatedly and it was suggested that certain cellular proteins could functionally compensate for E1A, leading to the expression of the early region 2 (E2)-encoded proteins and subsequently virus replication. Referring to this, the observation was named E1A-like activity. In this study, we investigated different cell cycle inhibitors with respect to their ability to increase viral DNA replication of dl70-3, an E1-deleted adenovirus. Our analyses of this issue revealed that in particular inhibition of cyclin-dependent kinases 4/6 (CDK4/6i) increased E1-independent adenovirus E2-expression and viral DNA replication. Detailed analysis of the E2-expression in dl70-3 infected cells by RT-qPCR showed that the increase in E2-expression originated from the E2-early promoter. Mutations of the two E2F-binding sites in the E2-early promoter (pE2early-LucM) caused a significant reduction in E2-early promoter activity in

Identifiants

DOI: 10.1128/jvi.00370-23 PMID: 37219458 PMC: PMC10308897
pubmed: 37219458
doi: 10.1128/jvi.00370-23
pmc: PMC10308897
doi:

Substances chimiques

Adenovirus E1A Proteins 0
DNA, Viral 0
Protein Kinase Inhibitors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0037023

Déclaration de conflit d'intérêts

The authors declare a conflict of interest. P.S.H. is co-founder of XVir Therapeutics GmbH. All other authors declare that they have no competing interests.

Références

J Biol Chem. 2002 Mar 22;277(12):10427-34
pubmed: 11788582
Nature. 1991 Jun 6;351(6326):494-7
pubmed: 1710781
J Virol. 1997 Jan;71(1):548-61
pubmed: 8985383
Cell. 1986 Apr 25;45(2):219-28
pubmed: 2938741
Mol Cell Biol. 1985 Apr;5(4):628-33
pubmed: 3872994
Mol Cell Biol. 1989 Nov;9(11):5143-53
pubmed: 2601713
J Biol Chem. 2009 Sep 25;284(39):26315-21
pubmed: 19648117
Nat Commun. 2022 Aug 10;13(1):4689
pubmed: 35948546
J Virol. 2011 Sep;85(17):8841-51
pubmed: 21715488
Semin Cancer Biol. 1995 Apr;6(2):109-16
pubmed: 7647307
Oncogene. 2007 Oct 18;26(48):6954-8
pubmed: 17486059
Clin Cancer Res. 2023 May 15;29(10):1996-2011
pubmed: 36892582
Proc Natl Acad Sci U S A. 1984 May;81(9):2713-7
pubmed: 6585823
J Virol. 2008 May;82(9):4511-20
pubmed: 18305049
Cell. 1981 Oct;26(2 Pt 2):213-20
pubmed: 7332929
Mol Pharm. 2011 Aug 1;8(4):1430-5
pubmed: 21682288
Cancer Res. 2004 Jan 1;64(1):322-8
pubmed: 14729641
Biochem J. 1991 Apr 15;275 ( Pt 2):281-99
pubmed: 1827253
Sci Transl Med. 2019 Aug 14;11(505):
pubmed: 31413145
Nature. 1998 Feb 5;391(6667):601-5
pubmed: 9468140
Cancer Cell. 2002 Aug;2(2):103-12
pubmed: 12204530
J Cell Sci. 2020 Nov 9;134(5):
pubmed: 32917739
J Virol. 1996 Dec;70(12):8944-60
pubmed: 8971024
FEBS Lett. 2019 Dec;593(24):3518-3530
pubmed: 31710378
Cancer Res. 2008 May 1;68(9):3193-203
pubmed: 18451145
Gene. 1987;58(2-3):243-56
pubmed: 2828188
PLoS One. 2013;8(2):e57340
pubmed: 23437375
Mol Biol Cell. 2005 Apr;16(4):2018-27
pubmed: 15703208
Cancer Res. 2006 Nov 1;66(21):10274-80
pubmed: 17079445
Curr Opin Mol Ther. 2001 Oct;3(5):454-63
pubmed: 11699889
Clin Cancer Res. 2019 Jan 1;25(1):21-28
pubmed: 30224338
Adv Cancer Res. 2016;131:133-57
pubmed: 27451126
Endocr Relat Cancer. 2019 Jan;26(1):R15-R30
pubmed: 30389903
Mol Cell Biol. 1988 Aug;8(8):3553-5
pubmed: 2974925
Cell Death Differ. 2008 Sep;15(9):1440-9
pubmed: 18451867
Nucleic Acids Res. 1995 Oct 25;23(20):4050-4
pubmed: 7479063
Front Biosci. 2002 May 01;7:d1369-95
pubmed: 11991831
Carcinogenesis. 1999 Jul;20(7):1161-8
pubmed: 10383885
Cell. 1987 May 22;49(4):507-13
pubmed: 2952280
Virology. 2015 Apr;478:99-111
pubmed: 25744056
Hum Gene Ther. 2019 Jan;30(1):44-56
pubmed: 29916265
Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8802-6
pubmed: 8090727
Cancer Res. 2006 Feb 1;66(3):1282-8
pubmed: 16452180
PLoS One. 2017 Jul 10;12(7):e0181012
pubmed: 28700677
Mol Cell Biol. 1984 May;4(5):867-74
pubmed: 6547205
Oncogene. 2002 Jul 4;21(29):4539-48
pubmed: 12085232
Cancer Res. 2002 Nov 1;62(21):6089-98
pubmed: 12414633
Mol Cancer. 2010 Jul 03;9:175
pubmed: 20598155
Hum Gene Ther. 2000 Sep 1;11(13):1933-48
pubmed: 10986565
J Mol Biol. 1996 May 24;258(5):736-46
pubmed: 8637006
mSphere. 2015 Nov 11;1(1):
pubmed: 27303679
BMC Cancer. 2010 Feb 23;10:57
pubmed: 20178585
Front Immunol. 2022 Aug 09;13:985622
pubmed: 36016945
Oncogene. 2007 May 24;26(24):3473-81
pubmed: 17146434

Auteurs

Maximilian Ehrenfeld (M)

Department of Urology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.

Felicia Segeth (F)

Department of Oral and Maxillofacial Surgery, Medical University of Innsbruck, Innsbruck, Austria.
Department of Molecular Biology, Leopold-Franzens-Universität Innsbruck, Austria.

Klaus Mantwill (K)

Department of Urology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.

Corinna Brockhaus (C)

Department of Urology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.

Yuling Zhao (Y)

Department of Urology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.

Christian Ploner (C)

Department of Plastic, Reconstructive and Aesthetic Surgery, Medical University of Innsbruck, Innsbruck, Austria.

Andreas Kolk (A)

Department of Oral and Maxillofacial Surgery, Medical University of Innsbruck, Innsbruck, Austria.

Jürgen E Gschwend (JE)

Department of Urology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.

Roman Nawroth (R)

Department of Urology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.

Per Sonne Holm (PS)

Department of Urology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Department of Oral and Maxillofacial Surgery, Medical University of Innsbruck, Innsbruck, Austria.
XVir Therapeutics GmbH, Munich, Germany.
ORCID: 0000-0002-1196-2323

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Virus › Virus à ADN › Adenoviridae › Targeting Cell Cycle Facilitates...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Antigènes viraux › Antigènes des virus oncogènes › Protéines E1A d'adénovirus › Targeting Cell Cycle Facilitates...
questionsmedicales.fr › Phénomènes chimiques › Phénomènes biochimiques › Sites de fixation › Targeting Cell Cycle Facilitates...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Cycle cellulaire › Targeting Cell Cycle Facilitates...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Targeting Cell Cycle Facilitates...
questionsmedicales.fr › Cellules › Targeting Cell Cycle Facilitates...
questionsmedicales.fr › Phénomènes génétiques › Réplication de l'ADN › Targeting Cell Cycle Facilitates...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ADN › ADN viral › Targeting Cell Cycle Facilitates...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Régulation de l'expression des gènes viraux › Targeting Cell Cycle Facilitates...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Targeting Cell Cycle Facilitates...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Génome › Composants de génome › Gènes › Composants de gène › Éléments de régulation transcriptionnelle › Régions promotrices (génétique) › Targeting Cell Cycle Facilitates...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéines kinases › Targeting Cell Cycle Facilitates...
questionsmedicales.fr › Phénomènes microbiologiques › Phénomènes physiologiques viraux › Réplication virale › Targeting Cell Cycle Facilitates...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Targeting Cell Cycle Facilitates...